Group · Molecular
High-throughput biological data, read for mechanism. We work mainly in oncogenomics, looking for the molecular events that separate one tumour from another and the biomarkers that make that difference actionable.
Genomics, transcriptomics, epigenomics, proteomics and metabolomics each describe one layer of a tumour. Integrated, they describe a system. We synthesise multi-dimensional data from international consortia — TCGA, GEO, ICGC — to characterise tumour heterogeneity and identify clinically actionable targets.
Bulk RNA-seq gives a high-resolution view of the transcriptome across a sample. We use it for differential expression, isoform discovery, gene fusion detection and alternative splicing analysis across pathological states.
scRNA-seq resolves expression to the individual cell, which is where the interesting heterogeneity usually lives. Our work here concerns the tumour microenvironment, rare cell populations, and the cell-state trajectories that accompany progression and immune response.
Where a target emerges from the omics work, we follow it structurally — binding-site characterisation, docking and stability assessment — to judge whether it is tractable.
Pan-cancer analysis reveals immunological and prognostic significance of CCT5 in human tumors, Scientific Reports, 2025.